TriSalus Life Sciences (TLSI) Interest & Investment Income (2021 - 2026)
TriSalus Life Sciences' (TLSI) quarterly Interest & Investment Income came in at $164000.0 in Q1 2026, up 121.62% year-on-year from $74000.0 in Q1 2025, and down 7.34% quarter-over-quarter from $177000.0 in Q4 2025.
TriSalus Life Sciences (TLSI) Interest & Investment Income (2021 - 2026) Analysis & Trends
TriSalus Life Sciences' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $164000.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 121.62% year-over-year to $164000.0 in Q1 2026; TTM through Mar 2026 was $645000.0, a 67.1% increase from a year earlier, with the FY2025 full-year figure at $555000.0, up 37.38% from the prior year.
- Interest & Investment Income retreated to $164000.0 in Q1 2026 per TLSI's latest filing, from $177000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $314714.0 in Q2 2022 and bottomed at $35000.0 in Q1 2023.
- The 5-year median for Interest & Investment Income is $105000.0 (2022), against an average of $122347.9.
- Across the five-year window, Interest & Investment Income soared 11171.99% in 2022 and sank 88.56% in 2023, its largest moves.
- Year by year, Interest & Investment Income stood at $105000.0 in 2022, then surged by 132.38% to $244000.0 in 2023, then plunged by 76.64% to $57000.0 in 2024, then surged by 210.53% to $177000.0 in 2025, then dropped by 7.34% to $164000.0 in 2026.
- Per Business Quant, the three latest TLSI Interest & Investment Income figures stand at $164000.0 (Q1 2026), $177000.0 (Q4 2025), and $170000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 106.00 Mn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 33.50 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 40.98 Mn |
| 10 | TriSalus Life Sciences | 222.14 Mn | 165.58 Mn | 7.67 Mn | 164,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164,000.00 |
| Dec 31, 2025 | 177,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 134,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 158,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | 92,000.00 |
| Dec 31, 2023 | 244,000.00 |
| Sep 30, 2023 | 116,000.00 |
| Jun 30, 2023 | 36,000.00 |
| Mar 31, 2023 | 35,000.00 |
| Dec 31, 2022 | 105,000.00 |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 314,714.00 |
| Mar 31, 2022 | 57,200.00 |
| Dec 31, 2021 | 7,916.00 |
| Sep 30, 2021 | 18,665.00 |
| Jun 30, 2021 | 2,792.00 |